Understanding on CRISPR/Cas9 mediated cutting-edge approaches for cancer therapeutics

The research focus on CRISPR/Cas9 has gained substantial concentration since the discovery of ‘an unusual repeat sequence’ reported by Ishino et al. (J Bacteriol 169:5429–5433, 1987) and the journey comprises the recent Nobel Prize award (2020), conferred to Emmanuelle Charpentier and Jennifer Doudn...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhattacharjee, Rudrarup, Das Roy, Lopamudra, Choudhury, Amarendranath
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9174617/
https://www.ncbi.nlm.nih.gov/pubmed/35674844
http://dx.doi.org/10.1007/s12672-022-00509-x
_version_ 1784722276687544320
author Bhattacharjee, Rudrarup
Das Roy, Lopamudra
Choudhury, Amarendranath
author_facet Bhattacharjee, Rudrarup
Das Roy, Lopamudra
Choudhury, Amarendranath
author_sort Bhattacharjee, Rudrarup
collection PubMed
description The research focus on CRISPR/Cas9 has gained substantial concentration since the discovery of ‘an unusual repeat sequence’ reported by Ishino et al. (J Bacteriol 169:5429–5433, 1987) and the journey comprises the recent Nobel Prize award (2020), conferred to Emmanuelle Charpentier and Jennifer Doudna. Cumulatively, the CRISPR has a short, compact, and most discussed success of its application in becoming one of the most versatile and paradigm shifting technologies of Biological Research. Today, the CRISPR/Cas9 genome editing system is almost ubiquitously utilized in many facets of biological research where its tremendous gene manipulation capability has been harnessed to create miracles. From 2012, the CRISPR/Cas 9 system has been showcased in almost 15,000 research articles in the PubMed database, till date. Backed by some strong molecular evidence, the CRISPR system has been utilized in a few clinical trials targeted towards various pathologies. While the area covered by CRISPR is cosmic, this review will focus mostly on the utilization of CRISPR/Cas9 technology in the field of cancer therapy.
format Online
Article
Text
id pubmed-9174617
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-91746172022-06-08 Understanding on CRISPR/Cas9 mediated cutting-edge approaches for cancer therapeutics Bhattacharjee, Rudrarup Das Roy, Lopamudra Choudhury, Amarendranath Discov Oncol Research The research focus on CRISPR/Cas9 has gained substantial concentration since the discovery of ‘an unusual repeat sequence’ reported by Ishino et al. (J Bacteriol 169:5429–5433, 1987) and the journey comprises the recent Nobel Prize award (2020), conferred to Emmanuelle Charpentier and Jennifer Doudna. Cumulatively, the CRISPR has a short, compact, and most discussed success of its application in becoming one of the most versatile and paradigm shifting technologies of Biological Research. Today, the CRISPR/Cas9 genome editing system is almost ubiquitously utilized in many facets of biological research where its tremendous gene manipulation capability has been harnessed to create miracles. From 2012, the CRISPR/Cas 9 system has been showcased in almost 15,000 research articles in the PubMed database, till date. Backed by some strong molecular evidence, the CRISPR system has been utilized in a few clinical trials targeted towards various pathologies. While the area covered by CRISPR is cosmic, this review will focus mostly on the utilization of CRISPR/Cas9 technology in the field of cancer therapy. Springer US 2022-06-08 /pmc/articles/PMC9174617/ /pubmed/35674844 http://dx.doi.org/10.1007/s12672-022-00509-x Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research
Bhattacharjee, Rudrarup
Das Roy, Lopamudra
Choudhury, Amarendranath
Understanding on CRISPR/Cas9 mediated cutting-edge approaches for cancer therapeutics
title Understanding on CRISPR/Cas9 mediated cutting-edge approaches for cancer therapeutics
title_full Understanding on CRISPR/Cas9 mediated cutting-edge approaches for cancer therapeutics
title_fullStr Understanding on CRISPR/Cas9 mediated cutting-edge approaches for cancer therapeutics
title_full_unstemmed Understanding on CRISPR/Cas9 mediated cutting-edge approaches for cancer therapeutics
title_short Understanding on CRISPR/Cas9 mediated cutting-edge approaches for cancer therapeutics
title_sort understanding on crispr/cas9 mediated cutting-edge approaches for cancer therapeutics
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9174617/
https://www.ncbi.nlm.nih.gov/pubmed/35674844
http://dx.doi.org/10.1007/s12672-022-00509-x
work_keys_str_mv AT bhattacharjeerudrarup understandingoncrisprcas9mediatedcuttingedgeapproachesforcancertherapeutics
AT dasroylopamudra understandingoncrisprcas9mediatedcuttingedgeapproachesforcancertherapeutics
AT choudhuryamarendranath understandingoncrisprcas9mediatedcuttingedgeapproachesforcancertherapeutics

Ejemplares similares